Dover misses Q2 estimates with revenue falling $39M short

source:

Related News

Jul 24 2026, 18:11

Regeneron's Yancopoulos holds 1,000 patents fueling drug pipeline

**George Yancopoulos has built Regeneron into a drug powerhouse through internal science, not acquisitions — a bet that's paid off with more than 1,000 patents and a string of blockbuster drugs.** George Yancopoulos, Regeneron's chief scientific officer and a company co-founder, holds more than 1,000 patents and has built the drugmaker's pipeline entirely through internal discovery rather than acquisitions. "We've shown that you can build a major pharmaceutical company by focusing on the science rather than the business development deals," Yancopoulos said in a recent interview. Regeneron's approach has produced blockbusters including Eylea for wet age-related macular degeneration, Dupixent for inflammatory conditions such as eczema and asthma, and REGEN-COV for Covid-19. The company's market capitalization has grown to more than $100 billion, making it one of the largest biotech firms globally by value. The strategy stands in contrast to peers such as Pfizer and AbbVie, which have relied heavily on large acquisitions to fill pipeline gaps. Regeneron's research and development spending as a percentage of revenue has consistently exceeded the industry average, according to company filings. ## A Pipeline Built on Biology Regeneron's discovery engine centers on its proprietary VelociSuite technologies, a suite of genetic engineering platforms that accelerate drug target identification and antibody development. The platform has generated more than a dozen approved drugs and dozens more in clinical development, spanning oncology, immunology, and genetic diseases. Yancopoulos, who joined Regeneron at its founding in 1988, has overseen the company's expansion from a startup with fewer than 50 employees to a global biopharmaceutical company with more than 12,000 staff. His patent portfolio — among the largest of any living scientist — covers foundational technologies in antibody discovery, gene editing, and cell-based assays. ## The R&D Dividend Regeneron's organic growth model has delivered consistent financial returns. The company reported $13.6 billion in revenue in 2024, driven largely by Dupixent, which it co-markets with Sanofi, and Eylea, co-marketed with Bayer. Dupixent alone generated more than $12 billion in global sales in 2024, making it one of the best-selling prescription drugs worldwide. The company's operating margin has averaged above 30% over the past five years, reflecting the cost advantage of internally developed drugs versus in-licensed or acquired assets, which typically carry higher royalty obligations and integration costs. For investors, the Yancopoulos-led strategy signals that Regeneron can sustain its innovation cycle without the dilution or execution risk that often accompanies large M&A. The next catalyst to watch is the late-stage readout for its investigational antibody targeting obesity, a market projected to exceed $100 billion annually by 2030. *This article is for informational purposes only and does not constitute investment advice.*

Jul 24 2026, 18:10

Strong earnings fail to lift stocks as 3 macro headwinds build

Stocks are declining even as companies deliver strong earnings, with a 30% surge in jet fuel costs and tightening financial conditions weighing on the outlook. "The earnings story is compelling, but markets are pricing in what comes next — higher costs, tighter liquidity, and the risk that demand softens," said Sarah Lin, equity strategist at Edgen. Jet fuel spot prices surged nearly 30% between July 2 and July 22 to $3.59 a gallon, according to Reuters data, adding $1.6 billion to American Airlines' projected fuel bill for the rest of the year. The carrier cut its full-year earnings forecast to around breakeven from an expected $1.5 billion in pretax profit. Delta Air Lines maintained its outlook while United Airlines raised the lower end of its forecast, though both cited fuel as a growing concern. The divergence between earnings and stock prices suggests investors are looking past current results to future headwinds. If the trend continues, it could signal a broader market correction, with sectors most exposed to input cost inflation facing the steepest pressure. Traders pointed to three overlapping catalysts behind the selloff: a rapid rise in commodity costs tied to geopolitical tensions, expectations that central banks will keep rates higher for longer, and growing evidence that corporate margins are peaking as input costs outpace pricing power. For airlines, the math is unforgiving. Every one-cent increase in American's average fuel price adds about $46 million to its annual expense, Chief Financial Officer Devon May said in an interview. A 10-cent increase would cost roughly $460 million, flowing almost entirely through to pretax earnings. American's projected fuel bill rose by about $550 million in the past week alone, May said. The fuel shock is rippling across the industry. Alaska Air Group declined to restore full-year guidance, while Southwest Airlines lowered the floor of its outlook. United said the rise in fuel prices since July 1 added $575 million to its expected third-quarter fuel bill and changed its guidance policy to use the latest available prices. The broader concern is that fuel is just one example of a wider cost squeeze. If other input costs follow the same trajectory, the earnings beat that investors are celebrating today could reverse in the quarters ahead. This article is for informational purposes only and does not constitute investment advice.

Jul 24 2026, 18:09

Trump threatens EU with tariffs as new trade levies hit 60 nations

President Donald Trump threatened the European Union with "substantial" tariffs Thursday, accusing the bloc of unfairly fining US technology companies, as a separate wave of forced-labor duties covering 60 nations took effect. "We commit to continuing to use tariffs and to negotiate deals to support the reindustrialization of our economy," US Trade Representative Jamieson Greer said in Senate testimony Wednesday. The new forced-labor tariffs, set between 10% and 12.5%, replace the temporary 10% global levy that expired at 12:01 a.m. ET Friday. The duties cover 99.4% of US trade, the Office of the US Trade Representative said. A senior administration official called it "the most sweeping international labor rights action any country has ever taken." The EU threat marks the latest escalation in Trump's tariff agenda after the Supreme Court struck down his "liberation day" duties in February. The White House this week also imposed 25% tariffs on Brazilian imports and 50% levies on Canadian goods set to begin next month, reintroducing uncertainty for global supply chains. The EU investigation targets what the administration described as unfair penalties against Google, Apple and other American technology companies. Trump said the bloc had been "robbing" US firms, though he did not specify a tariff rate or effective date for any potential retaliatory measures. The European Commission has levied more than $8 billion in antitrust fines on US tech companies over the past decade, including a record $4.3 billion penalty on Google in 2018. The latest trade actions show how Trump has shifted to using Section 301 of the Trade Act of 1974 — the same authority deployed during his first-term trade war with China — after the Supreme Court ruling. The previous 10% global tariff, imposed under Section 122, carried a 150-day timer that lapsed Friday. The last time Trump used Section 301 against a major trading partner was in 2019, when he imposed tariffs on $300 billion in Chinese goods, a move that reduced bilateral trade by roughly 15% over the following year, according to Census Bureau data. The forced-labor probe, launched in March alongside a separate investigation into excess manufacturing capacity by 16 economies, concluded that targeted countries failed to effectively ban forced labor practices in trade with the US. The second Section 301 investigation has yet to be finalized. The new duties do not stack on top of existing Section 232 steel and aluminum tariffs, a senior administration official said, but they add to a growing list of import taxes that have pushed up costs for American businesses. Trump has defended tariffs as tools for generating revenue and gaining leverage over trade partners, while critics argue they function as a tax on US importers and consumers. The Peterson Institute for International Economics has estimated that Trump's tariff rounds could cost the average US household more than $1,200 annually. The EU threat introduces a new front in Trump's trade agenda at a time when transatlantic economic relations were already strained. The previous US-EU tariff truce, negotiated during the Biden administration, covered industrial goods and avoided the technology sector. Any new duties targeting EU imports over tech fines would represent a significant expansion of the trade conflict, potentially affecting more than $500 billion in annual transatlantic goods trade. The administration's aggressive use of tariffs faces legal headwinds after the Supreme Court's February ruling invalidated Trump's across-the-board "liberation day" duties, forcing the White House to pursue narrower, statute-specific trade actions. The EU has previously signaled it would retaliate against any US tariffs with countermeasures of its own, a dynamic that could escalate into a full-scale transatlantic trade war. This article is for informational purposes only and does not constitute investment advice.